Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle.

[1]  Sung-Hoon Kim,et al.  Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells , 2021, Cells.

[2]  Koustav Pal,et al.  Prostate cancer: Therapeutic prospect with herbal medicine , 2021, Current research in pharmacology and drug discovery.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Fen Ma,et al.  Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer , 2021, Molecular oncology.

[5]  Jinyi Zhou,et al.  Characterization of ginsenoside compound K loaded ionically cross-linked carboxymethyl chitosan–calcium nanoparticles and its cytotoxic potential against prostate cancer cells , 2020, Journal of ginseng research.

[6]  Joshua M. Stuart,et al.  Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer , 2020, Clinical Cancer Research.

[7]  Anshul Sharma,et al.  Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities , 2020, Biomolecules.

[8]  Wei Zhang,et al.  CARM1 promotes non-small cell lung cancer progression through upregulating CCNE2 expression , 2020, Aging.

[9]  Yuzhuo Wang,et al.  PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. , 2020, Gene.

[10]  Lei Wang,et al.  Weighted gene co-expression network analysis identifies CCNA2 as a treatment target of prostate cancer through inhibiting cell cycle , 2020, Journal of Cancer.

[11]  Eunhee Kim,et al.  Ginsenoside Compound K Induces Ros-Mediated Apoptosis and Autophagic Inhibition in Human Neuroblastoma Cells In Vitro and In Vivo , 2019, International journal of molecular sciences.

[12]  J. Kim,et al.  AKT1-targeted proapoptotic activity of compound K in human breast cancer cells , 2019, Journal of ginseng research.

[13]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[14]  H. Kim,et al.  Compound K, a ginsenoside metabolite, plays an antiinflammatory role in macrophages by targeting the AKT1-mediated signaling pathway , 2018, Journal of ginseng research.

[15]  Chen Li,et al.  Ginsenoside metabolite compound K induces apoptosis and autophagy in non-small cell lung cancer cells via AMPK-mTOR and JNK pathways. , 2019, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[16]  E. Winquist,et al.  Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer , 2018, Expert opinion on emerging drugs.

[17]  Yan Yan,et al.  Compound K Induces Endoplasmic Reticulum Stress and Apoptosis in Human Liver Cancer Cells by Regulating STAT3 , 2018, Molecules.

[18]  Yicheng Wang,et al.  Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers , 2018, Front. Pharmacol..

[19]  Sang Yeol Lee.  Synergistic effect of maclurin on ginsenoside compound K induced inhibition of the transcriptional expression of matrix metalloproteinase-1 in HaCaT human keratinocyte cells , 2017, Journal of ginseng research.

[20]  J. Cho,et al.  The skin protective effects of compound K, a metabolite of ginsenoside Rb1 from Panax ginseng , 2017, Journal of ginseng research.

[21]  Huixia Lv,et al.  Targeted delivery of ginsenoside compound K using TPGS/PEG-PCL mixed micelles for effective treatment of lung cancer , 2017, International journal of nanomedicine.

[22]  ShaoChuang Wang,et al.  PKMYT1 promoted the growth and motility of hepatocellular carcinoma cells by activating beta‐catenin/TCF signaling , 2017, Experimental cell research.

[23]  S. Olesen,et al.  Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors. , 2017, Journal of medicinal chemistry.

[24]  Yicheng Wang,et al.  Food and Sex-Related Impacts on the Pharmacokinetics of a Single-Dose of Ginsenoside Compound K in Healthy Subjects , 2017, Front. Pharmacol..

[25]  J. Sohng,et al.  The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells , 2017, International journal of oncology.

[26]  E. Steyerberg,et al.  Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance , 2016, Medicine.

[27]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[28]  Zhenhai Zhang,et al.  Ginseng consumption and risk of cancer: A meta-analysis , 2015, Journal of ginseng research.

[29]  Emily J. Girard,et al.  Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. , 2015, Cell reports.

[30]  Xiaoxin Lan,et al.  Ginsenoside Compound K suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: A study in vitro and in vivo. , 2015, Life sciences.

[31]  Xuekun Song,et al.  CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  N. Seki,et al.  Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer , 2015, British Journal of Cancer.

[33]  Jian Zhang,et al.  Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. , 2015, Journal of thoracic disease.

[34]  Yi Pan,et al.  CytoNCA: A cytoscape plugin for centrality analysis and evaluation of protein interaction networks , 2015, Biosyst..

[35]  P. Kaldis,et al.  Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. , 2014, Cancer research.

[36]  K. Kang,et al.  Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity. , 2013, International journal of oncology.

[37]  R. Poon,et al.  The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery , 2013, Oncogene.

[38]  Jihui Wang,et al.  Compound K induces apoptosis of bladder cancer T24 cells via reactive oxygen species-mediated p38 MAPK pathway. , 2013, Cancer biotherapy & radiopharmaceuticals.

[39]  N. Bhattacharyya,et al.  MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells. , 2013, Biochemical and biophysical research communications.

[40]  M. Benkirane,et al.  Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. , 2013, Cell reports.

[41]  G. Bartsch,et al.  The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. , 2011, Cancer letters.

[42]  B. Bao,et al.  Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-κB Signaling Pathways , 2011, PloS one.

[43]  P. C. de Witt Hamer,et al.  WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe , 2011, Clinical Cancer Research.

[44]  Hai-Meng Zhou,et al.  Use of Serum Circulating Ccnb2 in Cancer Surveillance , 2010, The International journal of biological markers.

[45]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[46]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[47]  R. Sutherland,et al.  Expression and prognostic significance of cyclin B1 and cyclin A in non‐small cell lung cancer , 2009, Histopathology.

[48]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[49]  G. Bubley,et al.  Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 , 2006, Proceedings of the National Academy of Sciences.

[50]  S. Helms.  Cancer prevention and therapeutics: Panax ginseng. , 2004, Alternative medicine review : a journal of clinical therapeutic.

[51]  D. Korenaga,et al.  Clinicopathologic significance of cyclin A expression in colorectal carcinoma. , 2004, Journal of experimental & clinical cancer research : CR.

[52]  T. Yun.  Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. , 2003, Mutation research.

[53]  N. Rosen,et al.  Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. , 2000, Cancer research.

[54]  R. Chetty,et al.  Cyclin E in human cancers , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  K. Kobashi,et al.  Drug Metabolism: Intestinal Bacterial Hydrolysis is Required for the Appearance of Compound K in Rat Plasma after Oral Administration of Ginsenoside Rb1 from Panax ginseng , 1998 .

[56]  M. Sporn,et al.  Recent advances in chemoprevention of cancer. , 1997, Science.

[57]  A. Fattaey,et al.  Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity* , 1997, The Journal of Biological Chemistry.

[58]  K. Keyomarsi,et al.  The role of cyclin E in cell proliferation, development and cancer. , 1997, Progress in cell cycle research.

[59]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.